Bio-Rad Lab-B

Q2 FY2026 EarningsQ2 FY26 results exceeded expectations across major top and bottom-line metrics, with revenue reaching $651.0M vs. the $624.0M consensus (+4.33%). Non-GAAP diluted EPS of $2.62 was supported by a strong performance in Clinical Diagnostics, which grew 2.6% YoY, offset by a 4.1% decline in Life Sciences. Management reaffirmed its full-year outlook despite Life Science headwinds, while free cash flow of $66.7M surpassed the low-end analyst estimate of $118.5M for the first half, demonstrating solid operational discipline.